Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms by Grockowiak, E, Korn, C, Rak, J, Lysenko, V, Hallou, A, Panvini, FM, Williams, M, Fielding, C, Fang, Z, Khatib-Massalha, E, García-García, A, Li, J, Khorshed, RA, González-Antón, S, Baxter, EJ, Kusumbe, A, Wilkins, BS, Green, A, Simons, BD, Harrison, CN, Green, AR, Lo Celso, C, Theocharides, APA, Méndez-Ferrer, S

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial by Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ

Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis by Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S